Research programme: synthetic Fc-alpha-1 antitrypsin - Omni Bio Pharmaceutical

Drug Profile

Research programme: synthetic Fc-alpha-1 antitrypsin - Omni Bio Pharmaceutical

Alternative Names: Fc fusion recombinant AAT; Fc-AAT; Fc-AAT 2; Fc-AAT 3; Recombinant-Fc-AAT; Synthetic- Fc-alpha-1 antitrypsin; Synthetic-Fc-AAT

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Colorado at Denver
  • Developer Omni Bio Pharmaceutical; University of Colorado at Denver
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Recombinant fusion proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine protease inhibitors; Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gouty arthritis; Graft-versus-host disease; Myocardial infarction; Type 1 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gouty arthritis in Netherlands (SC)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Graft-versus-host-disease in USA (SC)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top